XRCC5 and cancer: LSVH with the XRCC5 rs1051685 heterozygous (AG) genotype were less likely to develop cancer at a younger age than those with the wild-type (AA) genotype, with a 31% estimated reduction in risk (Adj HR: 0.69 [CI, 0.48–0.99], p = 0.043) (Supplementary Table S4).